Medical Device News Magazine

RaySearch and Mevion to Develop Next-Generation Treatment Planning Techniques for FLASH Proton Radiotherapy Treatment

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

RaySearch Laboratories AB (publ) and Mevion Medical Systems, two companies that are leading the field of proton therapy, announce a collaboration to develop advanced treatment planning techniques for FLASH delivery with the MEVION S250i Proton Therapy System.

The collaboration will explore FLASH intensity modulated proton therapy (IMPT) delivery using a technique that supports the delivery of large-volume clinical FLASH fields through the combination of smaller fields, each delivered at FLASH dose rates which complements Mevion’s advanced HYPERSCAN delivery system.

Townsend Zwart, Vice President of Advanced Development, Mevion Medical Systems, says: “Mevion is pleased to continue our long partnership with RaySearch to develop ultra-high dose rate (FLASH) intensity modulated proton therapy. Optimizing FLASH delivery requires explicit consideration of the time dependent dose delivery and sequencing of proton spots. Overlapping spots or spots with multiple pulses may have complex FLASH weighting factors. Differing tissue types or tissue properties may also need to be included in an effective dose weighting model. The RaySearch development team is uniquely qualified to incorporate these features into a FLASH dose calculation module.”

Kjell Eriksson, Chief Science Officer, RaySearch, says: “RayStation already supports IMPT planning for Mevion’s HYPERSCAN system with Monte Carlo dose calculation for both optimization and final dose calculation. We are now excited to explore how RayStation can create optimal FLASH plans for the HYPERSCAN system and to further deepening our partnership.”

Since 2014, RaySearch and Mevion have collaborated to provide advanced treatment planning capabilities for Mevion’s HYPERSCAN pencil-beam scanning and Adaptive Aperture pMLC. Both companies will be exhibiting at the upcoming American Society for Radiation Oncology (ASTRO) annual meeting in Chicago, October 24–26. Attendees are invited to the respective booths to learn more.

* FLASH therapy is currently under preclinical research and is not yet available for commercial sale or clinical use.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”